Epkinly
Epkinly (epcoritamab) is a bispecific monoclonal antibody designed to treat certain types of relapsed or refractory B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. It works by binding to both cancer cells and immune cells to help the body's own T-cells recognize and destroy cancer cells. This medication is typically prescribed for patients who have received at least two prior lines of therapy.
Epkinly is an injectable immunotherapy for relapsed or refractory B-cell lymphomas that helps the immune system attack cancer cells.
Key facts at a glance
- RxNorm
- 2637401
- Generic
- Epkinly
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Epkinly is approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma (Grade 1-3a) in adults who have received at least two prior systemic therapies.
Epkinly is a bispecific CD20-directed CD3 T-cell engager. It simultaneously binds to CD20 proteins on the surface of B-cells (including cancer cells) and CD3 proteins on T-cells, bringing them into close proximity so that the T-cells can recognize and destroy the malignant B-cells.
Epkinly is administered as a subcutaneous injection, typically in increasing doses to help minimize side effects. Serious risks include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), serious infections, and neutropenia. Due to the risk of CRS, it is often initiated with a step-up dosing schedule and patients should be monitored closely during and after administration. A REMS (Risk Evaluation and Mitigation Strategy) program is in place for this medication.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy